Keywords: positive, pivotal, phase, iii, results, vicuron, dalbavancin
Positive pivotal Phase III results for Vicuron's dalbavancin; NDA filing on track
Article | 23 August 2004
USA-based Vicuron Pharmaceuticals has reported positive findings fromthree Phase III trials evaluating once-weekly dalbavancin in skin and soft tissue infections ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
